Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.
Soft Copy Attached
| # | Name | Date |
|---|---|---|
| 1 | 202047040191-STATEMENT OF UNDERTAKING (FORM 3) [16-09-2020(online)].pdf | 2020-09-16 |
| 2 | 202047040191-PROOF OF RIGHT [16-09-2020(online)].pdf | 2020-09-16 |
| 3 | 202047040191-PRIORITY DOCUMENTS [16-09-2020(online)].pdf | 2020-09-16 |
| 4 | 202047040191-POWER OF AUTHORITY [16-09-2020(online)].pdf | 2020-09-16 |
| 5 | 202047040191-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105) [16-09-2020(online)].pdf | 2020-09-16 |
| 6 | 202047040191-FORM FOR SMALL ENTITY(FORM-28) [16-09-2020(online)].pdf | 2020-09-16 |
| 7 | 202047040191-FORM 1 [16-09-2020(online)].pdf | 2020-09-16 |
| 8 | 202047040191-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [16-09-2020(online)].pdf | 2020-09-16 |
| 9 | 202047040191-DECLARATION OF INVENTORSHIP (FORM 5) [16-09-2020(online)].pdf | 2020-09-16 |
| 10 | 202047040191-COMPLETE SPECIFICATION [16-09-2020(online)].pdf | 2020-09-16 |
| 11 | 202047040191-Form26_Power of Attorney_28-09-2020.pdf | 2020-09-28 |
| 12 | 202047040191-Form1_After Filing_28-09-2020.pdf | 2020-09-28 |
| 13 | 202047040191-Correspondence_28-09-2020.pdf | 2020-09-28 |
| 14 | 202047040191-FORM 3 [15-02-2021(online)].pdf | 2021-02-15 |
| 15 | 202047040191.pdf | 2021-10-18 |
| 16 | 202047040191-RELEVANT DOCUMENTS [25-03-2022(online)].pdf | 2022-03-25 |
| 17 | 202047040191-WithDrawalLetter.pdf | 2022-05-23 |